Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Kathryn O'Driscoll net worth and biography

Kathryn O'Driscoll Biography and Net Worth

Insider of Zymeworks

Ms. O’Driscoll joined Zymeworks in October 2019 and currently serves as Chief People Officer. She brings a wealth of experience in the software and global health sectors. Prior to joining Zymeworks, she held a variety of Human Resource leadership positions for Microsoft and served as Chief Human Resources Officer for PATH, a global organization working to accelerate health equity. Most recently, she served as VP of People for Snowflake, the data warehouse built for the cloud, located in San Mateo, California. Ms. O’Driscoll recently served on the Board of Social Venture Partners as part of her long and continuing engagement with that organization. She invests time and resources to support organizations working toward equity and inclusion. She is a graduate of Pacific University in Oregon.

What is Kathryn O'Driscoll's net worth?: The estimated net worth of Kathryn O'Driscoll is at least $76,996.17 as of March 15th, 2021. Ms. O'Driscoll owns 5,003 shares of Zymeworks stock worth more than $76,996 as of November 15th. This net worth evaluation does not reflect any other assets that Ms. O'Driscoll may own. Learn More about Kathryn O'Driscoll's net worth.
How do I contact Kathryn O'Driscoll?: The corporate mailing address for Ms. O'Driscoll and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Kathryn O'Driscoll's contact information.
Has Kathryn O'Driscoll been buying or selling shares of Zymeworks?: Kathryn O'Driscoll has not been actively trading shares of Zymeworks during the past quarter. Most recently, Kathryn O'driscoll sold 786 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $34.72, for a transaction totalling $27,289.92. Following the completion of the sale, the insider now directly owns 5,003 shares of the company's stock, valued at $173,704.16. Learn More on Kathryn O'Driscoll's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Neil Josephson (Insider), Neil Klompas (CFO), Kathryn O'Driscoll (Insider), James Priour (Insider), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 40,583 shares worth more than $436,263.55. The most recent insider tranaction occured on January, 8th when CFO Christopher Astle sold 1,431 shares worth more than $16,055.82. Insiders at Zymeworks own 1.9% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/8/2024.

Kathryn O'Driscoll Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/15/2021	Sell	786	$34.72	$27,289.92	5,003
3/10/2021	Sell	568	$34.95	$19,851.60	6,357

Kathryn O'Driscoll Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $15.39

$15.00

$16.24

50 Day Range

MA: $13.51

$11.70

$17.40

2 Week Range

Now: $15.39

$7.54

$17.70

Volume

627,915 shs

Average Volume

625,659 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

This company will win the AI race

From Porter & Company | Ad